Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: PORTON BIOPHARMA LIMITED
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2016-11-16 to 2022-09-26
Current total value of award: $12323733
Description: EO14042: VACCINE TECHNOLOGIES TO ADVANCE NEXT GENERATION ANTHRAX VACCINES